Form 4: Greenwich LifeSciences CEO Patel Acquires 3,600 Shares of Common Stock
SEC Form 4 Filing
Snehal Patel, CEO and CFO of Greenwich LifeSciences, purchased 3,600 shares of common stock at $9.88 per share on April 25, 2025, increasing their direct holdings to 5,570,602 shares.
Summary
- On April 25, 2025, Snehal Patel, the CEO and CFO of Greenwich LifeSciences, acquired 3,600 shares of the company's common stock.
- The purchase price was $9.88 per share.
- Following this transaction, Patel directly owns 5,570,602 shares of Greenwich LifeSciences.
Sentiment
Score: 6
Explanation: Neutral sentiment. The document simply reports a transaction. The CEO buying shares is generally a positive sign, but without further context, it's difficult to gauge the overall impact.
Positives
- The CEO's purchase of shares could be interpreted as a positive signal about their confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders. Monitoring these filings can offer insights into management's perspective on the company's valuation and future performance.
Stakeholder Impact
- Shareholders may view the CEO's stock purchase as a positive signal.
Key Dates
| Date | Description |
|---|---|
| 04/25/2025 | Date of transaction: Snehal Patel purchased 3,600 shares of Greenwich LifeSciences common stock. |
| 04/29/2025 | Date of signature on the Form 4 filing. |
Keywords
Greenwich LifeSciences, GLSI, Snehal Patel, stock acquisition, Form 4, beneficial ownership, CEO, CFO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.